{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:03:25Z","timestamp":1784675005792,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Aging"],"DOI":"10.1038\/s41514-026-00392-8","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:15:26Z","timestamp":1778588126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aging dictates tumor-specific genomic alterations across cancer types"],"prefix":"10.1038","volume":"12","author":[{"given":"Isabella N.","family":"Grabski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime L.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hanahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin F.","family":"Gainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Haigis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael A.","family":"Irizarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia C.","family":"Haigis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"392_CR1","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1056\/NEJMp1912298","volume":"381","author":"VJ Dzau","year":"2019","unstructured":"Dzau, V. J., Inouye, S. K., Rowe, J. W., Finkelman, E. & Yamada, T. Enabling healthful aging for all - the national academy of medicine grand challenge in healthy longevity. N. Engl. J. Med. 381, 1699\u20131701 (2019).","journal-title":"N. Engl. J. Med."},{"key":"392_CR2","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/j.cell.2021.03.005","volume":"184","author":"JL Schneider","year":"2021","unstructured":"Schneider, J. L. et al. The aging lung: physiology, disease, and immunity. Cell 184, 1990\u20132019 (2021).","journal-title":"Cell"},{"key":"392_CR3","doi-asserted-by":"crossref","unstructured":"The importance of aging in cancer research. Nat. Aging 2, 365\u2013366, https:\/\/pubmed.ncbi.nlm.nih.gov\/37118075\/ (2022).","DOI":"10.1038\/s43587-022-00231-x"},{"key":"392_CR4","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1126\/science.aau3879","volume":"362","author":"I Martincorena","year":"2018","unstructured":"Martincorena, I. et al. Somatic mutant clones colonize the human esophagus with age. Science 362, 911\u2013917 (2018).","journal-title":"Science"},{"key":"392_CR5","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1126\/science.aaa6806","volume":"348","author":"I Martincorena","year":"2015","unstructured":"Martincorena, I. et al. Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880\u2013886 (2015).","journal-title":"Science"},{"key":"392_CR6","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1038\/s41416-022-01704-x","volume":"126","author":"E di Martino","year":"2022","unstructured":"di Martino, E. et al. Incidence trends for twelve cancers in younger adults-a rapid review. Br. J. Cancer 126, 1374\u20131386 (2022).","journal-title":"Br. J. Cancer"},{"key":"392_CR7","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1126\/science.ade7114","volume":"379","author":"M Giannakis","year":"2023","unstructured":"Giannakis, M. & Ng, K. A common cancer at an uncommon age. Science 379, 1088\u20131090 (2023).","journal-title":"Science"},{"key":"392_CR8","doi-asserted-by":"publisher","first-page":"e2328171","DOI":"10.1001\/jamanetworkopen.2023.28171","volume":"6","author":"B Koh","year":"2023","unstructured":"Koh, B. et al. Patterns in cancer incidence among people younger than 50 years in the US, 2010 to 2019. JAMA Netw. Open 6, e2328171 (2023).","journal-title":"JAMA Netw. Open"},{"key":"392_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ygyno.2004.12.026","volume":"97","author":"HA Maas","year":"2005","unstructured":"Maas, H. A., Kruitwagen, R. F., Lemmens, V. E., Goey, S. H. & Janssen-Heijnen, M. L. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol. Oncol. 97, 104\u2013109 (2005).","journal-title":"Gynecol. Oncol."},{"key":"392_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.breast.2021.12.006","volume":"61","author":"HJ Kim","year":"2022","unstructured":"Kim, H. J., Kim, S., Freedman, R. A. & Partridge, A. H. The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: a U.S. SEER database analysis. Breast 61, 77\u201383 (2022).","journal-title":"Breast"},{"key":"392_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jamaoncol.2015.4482","volume":"2","author":"AG Sacher","year":"2016","unstructured":"Sacher, A. G. et al. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. JAMA Oncol. 2, 313\u2013320 (2016).","journal-title":"JAMA Oncol."},{"key":"392_CR12","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"APG Consortium","year":"2017","unstructured":"Consortium, A. P. G. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 7, 818\u2013831 (2017).","journal-title":"Cancer Discov."},{"key":"392_CR13","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.amepre.2013.10.029","volume":"46","author":"MC White","year":"2014","unstructured":"White, M. C. et al. Age and cancer risk: a potentially modifiable relationship. Am. J. Prev. Med 46, S7\u2013S15 (2014).","journal-title":"Am. J. Prev. Med"},{"key":"392_CR14","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/jso.27239","volume":"127","author":"JA Santamaria-Barria","year":"2023","unstructured":"Santamaria-Barria, J. A. et al. Age-related next-generation sequencing mutational analysis in 1196 melanomas. J. Surg. Oncol. 127, 1187\u20131195 (2023).","journal-title":"J. Surg. Oncol."},{"key":"392_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5826\/dpc.0901a13","volume":"9","author":"A Spathis","year":"2019","unstructured":"Spathis, A. et al. BRAF mutation status in primary, recurrent, and metastatic malignant melanoma and its relation to histopathological parameters. Dermatol Pract. Concept 9, 54\u201362 (2019).","journal-title":"Dermatol Pract. Concept"},{"key":"392_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target Ther. 6, 386 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"392_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.18632\/oncotarget.28612","volume":"15","author":"E Toye","year":"2024","unstructured":"Toye, E., Chehrazi-Raffle, A., Hwang, J. & Antonarakis, E. S. Targeting the multifaceted BRAF in cancer: new directions. Oncotarget 15, 486\u2013492 (2024).","journal-title":"Oncotarget"},{"key":"392_CR18","volume":"6","author":"JA Lavery","year":"2022","unstructured":"Lavery, J. A. et al. A scalable quality assurance process for curating oncology electronic health records: the project GENIE Biopharma Collaborative Approach. JCO Clin. Cancer Inf. 6, e2100105 (2022).","journal-title":"JCO Clin. Cancer Inf."},{"key":"392_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.700568","volume":"11","author":"L Harbers","year":"2021","unstructured":"Harbers, L. et al. Somatic copy number alterations in human cancers: an analysis of publicly available data from The Cancer Genome Atlas. Front. Oncol. 11, 700568 (2021).","journal-title":"Front. Oncol."},{"key":"392_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","volume":"36","author":"H Rizvi","year":"2018","unstructured":"Rizvi, H. et al. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J. Clin. Oncol. 36, 633\u2013641 (2018).","journal-title":"J. Clin. Oncol."},{"key":"392_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41588-023-01355-5","volume":"55","author":"A Ravi","year":"2023","unstructured":"Ravi, A. et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nat. Genet. 55, 807\u2013819 (2023).","journal-title":"Nat. Genet."},{"key":"392_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991091","volume":"13","author":"X Shang","year":"2022","unstructured":"Shang, X. et al. PTPRD\/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types. Front. Immunol. 13, 991091 (2022).","journal-title":"Front. Immunol."}],"container-title":["npj Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41514-026-00392-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41514-026-00392-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41514-026-00392-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T22:50:08Z","timestamp":1784674208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41514-026-00392-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["392"],"URL":"https:\/\/doi.org\/10.1038\/s41514-026-00392-8","relation":{},"ISSN":["2731-6068"],"issn-type":[{"value":"2731-6068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.L.S. has received honoraria from the Academy of Continued Healthcare Learning, Springer Healthcare, Targeted Oncology, Total Health Conferencing, DAVA Oncology, and Physicians\u2019 Education Resource; travel support from DAVA Oncology; and research funding from Gilead. A.R. consults for Halo LLC and has received research support from IBM to their institution. J.F.G. has served as a compensated consultant for Amgen, AstraZeneca, Mariana Therapeutics, Mirati Therapeutics, Merus Pharmaceuticals, Nuvalent, Pfizer, Novocure, AI Proteins, Novartis, Silverback Therapeutics, Sanofi, Blueprint Medicines, Bristol Myers Squibb, Genentech, Gilead Sciences, Revolution Medicines, Janssen, ITeos Therapeutics, Jounce Therapeutics, Karyopharm Therapeutics, Lilly\/Loxo, Merck, Moderna Therapeutics, and Takeda; has received honoraria from Novartis, Merck, Pfizer, and Takeda; has received institutional research funding from Adaptimmune, Alexo Therapeutics, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Jounce Therapeutics, Merck, Moderna Therapeutics, Novartis, NextPoint Therapeutics, and Palleon Pharmaceuticals; has received additional research support from Novartis, Genentech, and Takeda; holds equity in AI Proteins; and has an immediate family member who holds equity in and is employed by Ironwood Pharmaceuticals. M.C.H. serves on the scientific advisory boards of MitoQ, Alixia Therapeutics, Samyang Roundsquare, and Minovia, and is a scientific founder and member of the scientific advisory board for Refuel Bio. M.C.H. receives unrelated research funding from Refuel Bio. The other authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"98"}}